-
Company Insights
Innovation and Patenting activity of TaiGen Biopharmaceuticals Holdings Ltd Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of TaiGen Biopharmaceuticals Holdings Ltd Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
Hepatitis C – Drugs In Development, 2023
Global Markets Direct’s, ‘Hepatitis C - Drugs In Development, 2023’, provides an overview of the Hepatitis C pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hepatitis C, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Influenza A Virus, H7N9 Subtype Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Influenza A Virus, H7N9 Subtype Infections - Drugs In Development, 2023’, provides an overview of the Influenza A Virus, H7N9 Subtype Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Influenza A Virus, H7N9 Subtype Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Community Acquired Pneumonia – Drugs In Development, 2023
Global Markets Direct’s, ‘Community Acquired Pneumonia - Drugs In Development, 2023’, provides an overview of the Community Acquired Pneumonia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Community Acquired Pneumonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Avian Influenza – Drugs In Development, 2023
Global Markets Direct’s, ‘Avian Influenza - Drugs In Development, 2023’, provides an overview of the Avian Influenza pipeline landscape. The report provides comprehensive information on the therapeutics under development for Avian Influenza, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Influenzavirus B Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Influenzavirus B Infections - Drugs In Development, 2023’, provides an overview of the Influenzavirus B Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Influenzavirus B Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Influenzavirus A Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Influenzavirus A Infections - Drugs In Development, 2023’, provides an overview of the Influenzavirus A Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Influenzavirus A Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ASP-1002 in Metastatic Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ASP-1002 in Metastatic Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ASP-1002 in Metastatic Ovarian Cancer Drug Details: ASP-1002 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Oxfendazole in Trichuriasis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Oxfendazole in Trichuriasis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Oxfendazole in Trichuriasis Drug Details: Oxfendazole is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – WMS-1 in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - WMS-1 in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.WMS-1 in Bile Duct Cancer (Cholangiocarcinoma) Drug Details:WMS-1 is under development...